Tasly Pharmaceutical Group Future Growth

Future criteria checks 2/6

Tasly Pharmaceutical Group is forecast to grow earnings and revenue by 22.7% and 6.9% per annum respectively. EPS is expected to grow by 22.8% per annum. Return on equity is forecast to be 10.1% in 3 years.

Key information

22.7%

Earnings growth rate

22.8%

EPS growth rate

Pharmaceuticals earnings growth	18.9%
Revenue growth rate	6.9%
Future return on equity	10.1%
Analyst coverage	Good
Last updated	08 Nov 2024

Recent future growth updates

Recent updates

Investors Continue Waiting On Sidelines For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Nov 17

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Jul 22

Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Jun 13

The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet

May 13

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Apr 26

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Mar 15

Earnings and Revenue Growth Forecasts

SHSE:600535 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	10,074	1,489	N/A	1,919	8
12/31/2025	9,424	1,305	N/A	1,528	8
12/31/2024	8,911	1,021	N/A	1,404	8
9/30/2024	8,565	881	2,033	2,676	N/A
6/30/2024	8,654	1,026	2,050	2,621	N/A
3/31/2024	8,638	1,102	1,551	2,088	N/A
12/31/2023	8,674	1,071	1,907	2,576	N/A
9/30/2023	9,076	1,112	1,768	2,287	N/A
6/30/2023	8,996	859	1,950	2,496	N/A
3/31/2023	8,847	558	1,787	2,347	N/A
12/31/2022	8,637	-264	1,875	2,280	N/A
9/30/2022	8,315	534	1,313	1,803	N/A
6/30/2022	8,159	940	1,356	1,782	N/A
3/31/2022	8,063	1,478	1,964	2,480	N/A
12/31/2021	7,952	2,359	2,229	2,801	N/A
9/30/2021	7,955	1,507	2,249	2,739	N/A
6/30/2021	8,779	1,442	1,615	2,145	N/A
3/31/2021	11,387	1,154	1,736	2,163	N/A
12/31/2020	13,576	1,126	1,382	1,791	N/A
9/30/2020	16,298	969	966	1,550	N/A
6/30/2020	18,205	789	1,467	2,102	N/A
3/31/2020	18,380	848	764	1,455	N/A
12/31/2019	18,998	1,001	949	1,680	N/A
9/30/2019	19,057	1,308	770	1,597	N/A
6/30/2019	18,931	1,519	875	1,718	N/A
3/31/2019	18,609	1,622	796	1,601	N/A
12/31/2018	17,990	1,545	714	1,494	N/A
9/30/2018	17,957	1,607	907	1,432	N/A
6/30/2018	17,306	1,545	N/A	1,023	N/A
3/31/2018	16,699	1,430	N/A	75	N/A
12/31/2017	16,094	1,377	N/A	-796	N/A
9/30/2017	15,497	1,312	N/A	-637	N/A
6/30/2017	14,811	1,248	N/A	-692	N/A
3/31/2017	14,148	1,218	N/A	298	N/A
12/31/2016	13,945	1,176	N/A	1,154	N/A
9/30/2016	13,454	1,263	N/A	759	N/A
6/30/2016	13,391	1,333	N/A	840	N/A
3/31/2016	13,294	1,410	N/A	502	N/A
12/31/2015	13,228	1,479	N/A	340	N/A
9/30/2015	12,742	1,447	N/A	351	N/A
6/30/2015	12,698	1,454	N/A	326	N/A
3/31/2015	12,640	1,429	N/A	326	N/A
12/31/2014	12,578	1,368	N/A	617	N/A
9/30/2014	12,234	1,335	N/A	810	N/A
6/30/2014	11,816	1,242	N/A	602	N/A
3/31/2014	11,394	1,138	N/A	480	N/A
12/31/2013	11,108	1,098	N/A	345	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600535's forecast earnings growth (22.7% per year) is above the savings rate (2.8%).

Earnings vs Market: 600535's earnings (22.7% per year) are forecast to grow slower than the CN market (26.3% per year).

High Growth Earnings: 600535's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 600535's revenue (6.9% per year) is forecast to grow slower than the CN market (13.9% per year).

High Growth Revenue: 600535's revenue (6.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 600535's Return on Equity is forecast to be low in 3 years time (10.1%).

Tasly Pharmaceutical Group Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 14%

Price target increased by 8.7% to CN¥16.17

Price target decreased by 7.0% to CN¥13.88

Price target increased by 10% to CN¥12.76

Price target decreased by 13% to CN¥10.64

Consensus EPS estimates fall by 19%

Recent updates

Investors Continue Waiting On Sidelines For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Consensus EPS estimates fall by 14%

Third quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.22 in 3Q 2023)

Upcoming dividend of CN¥0.26 per share

Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 23% overvalued

Is Tasly Pharmaceutical Group (SHSE:600535) Using Too Much Debt?

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2024 Results on Aug 24, 2024

Price target increased by 8.7% to CN¥16.17

Estimating The Intrinsic Value Of Tasly Pharmaceutical Group Co., Ltd (SHSE:600535)

Now 20% overvalued

Dividend of CN¥0.33 announced

The Market Doesn't Like What It Sees From Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Earnings Yet

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 1Q 2023)

Tasly Pharmaceutical Group's (SHSE:600535) Solid Earnings Have Been Accounted For Conservatively

Price target decreased by 7.0% to CN¥13.88

Tasly Pharmaceutical Group Co., Ltd, Annual General Meeting, May 08, 2024

Now 21% undervalued after recent price drop

Tasly Pharmaceutical Group Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

Does Tasly Pharmaceutical Group (SHSE:600535) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 16%

Now 22% undervalued after recent price drop

ShuYu Civilian Pharmacy Corp., Ltd. Scraps Plan to Buy Stake in Tasly Pharmaceutical's Two Units

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.047 in 3Q 2022)

Tasly Pharmaceutical Group Co., Ltd to Report Q3, 2023 Results on Oct 28, 2023

Price target increased by 10% to CN¥12.76

Price target decreased by 13% to CN¥10.64

Consensus EPS estimates fall by 19%

Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.10 in 2Q 2022)

Now 21% undervalued after recent price drop

Consensus EPS estimates increase by 12%

Tasly Pharmaceutical Group Co., Ltd to Report First Half, 2023 Results on Aug 26, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued

Price target increased by 9.3% to CN¥12.10

Price target increased by 7.3% to CN¥11.79

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 8.0% to CN¥10.99

Consensus EPS estimates fall by 35%

Investor sentiment improves as stock rises 16%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.047 (vs CN¥0.32 in 3Q 2021)

Price target decreased to CN¥10.19

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 2Q 2021)

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CN¥14.34

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Price target increased to CN¥16.52

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall to CN¥1.03

Third quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.27 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥0.26 in 2Q 2020)

Consensus revenue estimates fall to CN¥7.67b

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.20 in 1Q 2020)

Tasly Pharmaceutical Group Co., Ltd to Report Fiscal Year 2020 Results on Mar 30, 2021

Tasly Pharmaceutical Group Co., Ltd(XSSC:600535) dropped from S&P Global BMI Index

New 90-day low: CN¥13.57

New 90-day low: CN¥14.49

Price target raised to CN¥19.43

New 90-day low: CN¥14.83

New 90-day low: CN¥16.61